TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A South Asian physician says she was screened for diabetes at a BMI of 23 but could not qualify for a GLP-1 weight-loss drug at a BMI of 26.5 without another qualifying condition. Her account, published in MedPage Today, describes a mismatch between ethnicity-adjusted clinical guidance and insurer criteria that often use BMI thresholds of 30, or 27 with a weight-related condition.
A South Asian physician says she was screened for diabetes once her BMI passed 23, in line with guidance that Asian Americans can face diabetes risk at lower body weights, but was denied a GLP-1 weight-loss drug at a BMI of 26.5 because she did not meet the insurer’s stated eligibility criteria. In a first-person report published by MedPage Today on October 31, Hamayle Saeed, MD, describes a mismatch between ethnicity-specific clinical guidance and coverage rules commonly tied to BMI thresholds of 30, or 27 with a weight-related condition.
Saeed writes that she does not have diabetes and therefore does not meet the BMI threshold she describes for GLP-1 weight-loss treatment: 30, or 27 with at least one weight-related condition. She contrasts that with the American Diabetes Association’s screening guidance, which she says calls for diabetes screening in Asian Americans beginning at BMI 23. Her account is a physician’s personal experience; it does not establish how every insurer or clinician would handle an individual request.
The report also points to recent coverage reductions. Saeed says Medi-Cal ended coverage for GLP-1 drugs used for weight loss in January and MassHealth followed in July. Those dates and policies are presented in her article; the supplied material does not include statements from either program or details about exceptions, appeals, or coverage for other medical indications.
Saeed cites a 2026 analysis of 352 GLP-1 trials, reporting that BMI eligibility criteria would include 41.5% of non-Asian American adults, compared with 13.5% of Asian Americans and 7.2% of Koreans. She says other cited trial criteria, including blood sugar, kidney and liver measures, admitted more than 93% of each group. The figures concern eligibility under the analyzed trial criteria, not approval rates for prescriptions or insurance coverage.
How BMI Rules Shape Drug Access
The issue affects whether patients who may face elevated metabolic risk at lower BMI can access treatment before reaching thresholds designed around different populations. Saeed argues that using a single BMI cutoff can leave Asian patients screened earlier for diabetes but less likely to qualify for weight-loss medication through trial criteria or payer authorization rules.
Coverage decisions have practical consequences because a prescription and insurance payment are separate matters. Even where a clinician considers a drug appropriate, a payer may require documentation tied to its own criteria. Saeed’s example highlights how clinical risk guidance, drug labels and coverage forms can use different definitions, leaving patients and prescribers to resolve the discrepancy.
The cited evidence may inform debate about whether eligibility should account for ethnicity-specific risk. It does not, by itself, establish that every Asian patient below BMI 30 should receive a GLP-1 drug, or that a particular coverage policy is medically or financially justified. Treatment decisions and coverage depend on individual circumstances and the applicable rules.
Products Worth Considering
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Withings BPM Connect Smart Blood Pressure Monitor
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
The Evidence Behind Lower Cutoffs
Saeed says Asian populations can have more visceral fat and less muscle at a given BMI than people of European descent, potentially contributing to metabolic risk at lower scale readings. She cites the World Health Organization’s 2004 action points for Asian populations, BMI 23 and 27.5, and a study of nearly 1.5 million adults in England. In that study, she reports, the BMI associated with the diabetes risk seen in white adults at BMI 30 was 23.9 for South Asian adults and 26.9 for Chinese adults.
The report also describes a 2025 study, STEP 11, conducted in South Korea and Thailand using a local obesity definition of BMI 25 or higher. Saeed says participants taking semaglutide 2.4 mg lost 16% of body weight, compared with 3.1% for placebo. A post hoc analysis of 68 participants who began below BMI 30 found losses of 17.6% among 45 semaglutide recipients and 4.4% among 23 placebo recipients. These are study findings as reported by Saeed, not a guarantee of results for individuals.
She also notes that the 2026 ADA standards advise clinicians to confirm excess adiposity using cutoffs appropriate to ethnicity and specifically name South Asian patients. According to the article, current U.S. labels for Wegovy and Zepbound state their indications in terms of obesity or overweight with a weight-related condition without stating a numerical BMI in that indication, while payer forms may still rely on numeric cutoffs.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5. Only one of them was written with an Asian body in mind.”
— Hamayle Saeed, MD, in MedPage Today
Coverage Rules Still Vary
The supplied report does not identify the physician’s insurer, provide the denial letter, or show whether an appeal was filed. It is also unclear which plans currently use BMI cutoffs of 30 and 27, how frequently exceptions are granted, and whether the cited state-program coverage changes apply uniformly across all patients and indications.
The article presents research and policy arguments for ethnicity-specific thresholds, but the supplied material does not include responses from insurers, drug manufacturers, Medi-Cal, MassHealth or federal regulators. Nor does it establish that the reported trial results should change a particular patient’s treatment. The precise relationship between updated product-label language and each payer’s authorization policy remains unresolved in the material provided.
Whether Payers Revise Their Criteria
The next development to watch is whether insurers and public programs revise prior authorization forms to reflect ethnicity-specific clinical guidance or evidence from trials that enrolled patients at lower BMI thresholds. Saeed’s report does not announce a policy change or give a timetable for one.
For now, patients and clinicians may need to check the criteria in the relevant plan and seek clarification about appeals or exceptions. Any future change will depend on decisions by payers and health programs, alongside clinical guidance and additional evidence about benefits, risks and appropriate eligibility.
Key Questions
Why did the physician say she was screened at BMI 23 but denied a GLP-1 drug?
She says diabetes screening guidance for Asian Americans begins at a lower BMI, while the weight-loss drug criteria she encountered required a BMI of 30, or 27 with a weight-related condition. At BMI 26.5, without diabetes, she said she met neither drug threshold.
Does a BMI of 23 automatically qualify an Asian patient for a GLP-1 drug?
No. The report describes a diabetes-screening threshold, not automatic eligibility for a prescription or insurance coverage. Drug decisions and payer requirements depend on the individual’s health circumstances and the applicable plan rules.
What did the cited STEP 11 study find?
As summarized in Saeed’s report, the study in South Korea and Thailand found average weight loss of 16% with semaglutide 2.4 mg, compared with 3.1% with placebo. A post hoc analysis of 68 participants who began below BMI 30 reported losses of 17.6% and 4.4%, respectively. These study results do not predict an individual patient’s outcome.
Have U.S. GLP-1 labels changed their BMI thresholds?
Saeed writes that the 2026 labels for Wegovy and Zepbound describe the relevant indications without stating a numerical BMI in the indication. She says payer prior authorization forms may still use thresholds of 30, or 27 with a qualifying condition; the supplied material does not detail each insurer’s current rules.
Source: medpagetoday.com
